ArticleDiscover oncology2026
The MAD2L1-FOXM1 axis negatively regulates CD4⁺ T cell and macrophages infiltration in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) exhibits high genetic heterogeneity and an immunosuppressive tumor microenvironment (TME), often characterized by reduced immune cell infiltration. Tumor-intrinsic regulators of cell cycle and genomic stability, such as MAD2L1, may also influence immune evasion, but their mechanistic role in LUAD remains unclear.
methodsCo-expression profiling was carried out to identify genes positively and negatively associated with MAD2L1 by using Correlation AnalayzeR and was corroborated using ENCORI, GEPIA2 and TIMER2.0 databases. Subsequent prognostic evaluation for all the genes was performed by using KM Plotter. The Spring Viewer transcriptomic database was used to assess the immune cell infiltration patterns correlating with these genes in NSCLC and the association was evaluated using the GSCA and TIMER2.0 databases. Additionally, the expression dynamics across pathological stages was determined by using GSCA.
resultsFOXM1 was previously identified as a key upstream regulator of MAD2L1, with co-expression analysis revealing strong positive associations with cell cycle regulators (BIRC5, BUB1B, TTK, CCNA2, DLGAP5) and negative associations with immune-related genes (IL3RA, MPEG1, NCKAP1L, GIMAP8, MS4A14). High MAD2L1 and its positive gene panel correlated with reduced CD4⁺ T cell infiltration, while the negative panel correlated with macrophage-rich TMEs. Stage-wise analysis showed an increase in the positive panel and a decrease in the negative panel from stage I to IV.
conclusionThe MAD2L1 axis emerges as a potential driver of immune exclusion in LUAD by suppressing CD4⁺ T cell infiltration, linking tumor proliferation to immune evasion. Targeting this axis may offer a strategy to restore anti-tumor immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.